Sinovac Reports Unaudited Second Quarter Financial Results
The following excerpt is from the company's SEC filing
BEIJING, Aug.14, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:
SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter and half year financial
results for the period ended June 30, 2014.
·Quarterly sales were $12.1 million, a decrease of 30.7% from $17.5
million in the prior year period. Sales for the first six months were $25.6 million, a decrease of 6.8% YoY from $27.5 million.
·Net loss attributable to common stockholders was $2.2 million, or
$(0.04) per basic and diluted share, compared to net income attributable to common stockholders
of $1.3 million, or $0.02 per basic
and diluted share, in the second quarter of 2013.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented,
"While sales were impacted during the second quarter by short-term challenges from the external market environment, we are
continuing to grow our sales channels and make strong progress in the development of our pipeline vaccines."
"In July, we received the first tranche of our RMB 60 million
government grant to build a dedicated facility for the production of the EV71 vaccine, which is currently under review by the Center
for Drug Evaluation. During the second quarter, we received our clinical trial license for the pneumococcal polysaccharide vaccine
(PPV) from the CFDA and expect to begin trials later this year."
"Although we experienced decreased sales in the second
quarter, we remain confident in our ability to execute our proven sales and marketing strategies, and continue to develop new vaccines
that are both effective and safe. We expect these initiatives to meaningfully contribute to our performance as market conditions
improve." Mr. Yin concluded.
Public Tenders Sinovac has been selected by the
Beijing Health Bureau as the sole supplier of inactivated hepatitis A vaccine in pre-filled syringe dosage to the Expanded Program
of Immunization (EPI) for Beijing. The tender is valued at approximately RMB 16 million. The vaccines purchased by the Beijing
Health Bureau will be used for the period from 2014 to 2016. The Company expects to begin delivery in the coming months.
Additionally, Sinovac has also been selected by the Beijing
Centers for Disease Control and Prevention to be a supplier of the seasonal influenza vaccine to the citizens of Beijing for 2014.
The Company expects to begin delivery in the third quarter of 2014.
International Sales to Mexico Sinovac obtained its
commercialization license for Anflu in Mexico late last year. In early July, the Company delivered its first order of 150,000 doses
of Anflu to Mexico, as it continues its efforts in international market expansions.
PPV The Company received clinical trial approval
for its PPV in May. Sinovac has selected a site for the clinical trial and its draft proposal is currently under expert review.
The Company expects clinical trials to begin by the end of 2014, following approval by an ethics committee.
Government Grant In April, Sinovac received approval
for a RMB 60 million government grant from China's Ministry of Finance, National Development and Reform Commission, Ministry of
Industry and Information Technology, and National Health and Family Planning Commission for construction of the Company's dedicated
EV71 vaccine production facility. Sinovac received the first RMB 20 million of the grant in July. The remainder will be provided
once construction and approval criteria are met.
VAT Rate Reduction The value added tax (VAT) rate
applied to the sales of Sinovac's vaccine products has been reduced to 3% from 6%, as authorized by the Ministry of Finance and
State Administration of Taxation of China. The reduced VAT rate was effective July 1, 2014, and therefore did not impact second
quarter results. Going forward, the reduced VAT rate will contribute to an improvement in the profitability of the Company's vaccines
in Chinese market.
In the second quarter 2014, total sales were $12.1 million,
a decrease of 30.7% from $17.5 million during the same period in 2013. This decrease was primarily due to softer demand in the
private vaccine market. China's CDCs have been also more conservative in their vaccination programs. Nevertheless, the Company
achieved record sales in the second quarter of 2013, which resulted in a higher basis for year-over-year comparison.
Gross profit was $9.1 million in the second quarter 2014, compared
to $13.6 million in the prior year period. Gross margin decreased to 75.0% from 77.9% in the prior year period. The slight decrease
in gross margin is attributable to idle capacity in the Company's influenza facility during the second quarter, which was charged
to cost of goods sold.
Selling, general and administrative expenses for the second
quarter 2014 were $8.6 million, compared to $8.8 million in the same period of 2013.
R&D expenses for the second quarter of 2014 were $3.3 million,
a $1.2 million increase over the same period in 2013. These expenses are primarily related to the continued advancement of pipeline
vaccine candidates, including sIPV, EV71, PPV, and varicella vaccine.
Net loss attributable to common stockholders for the second
quarter of 2014 was $2.2 million, or $ (0.04) per basic and diluted share, compared to a net income attributable to common stockholders
of $1.3 million, or $0.02 per basic and diluted share, in the same period last year.
Total sales for the first half of 2014 were $25.6 million, a
decrease of 6.8% from $27.5 million in the same period of 2013. Sales for the first half of 2014 were impacted by decreased sales
of the Company's hepatitis A vaccine, Healive, as a result of the challenging environment in the private-pay market.
Gross profit for the first half of 2014 was $19.3 million, a
decrease of 6.4% from $20.7 million in the same period of 2013. Gross margin was 75.4% in the first half of 2014, compared to 75.1%
in the same period of 2013.
Selling, general and administrative expenses for the first half
of 2014 were $16.4 million, compared to $15.9 million for the same period of 2013.
R&D expenses in the first half of 2014 were $5.0 million,
compared to $3.9 million in the same period of 2013. These expenses are primarily related to the continued advancement of pipeline
Net loss attributable to stockholders in the first half of 2014
was $2.2 million or $(0.04) per basic and diluted share, compared to a net loss of $0.7 million, or $(0.01) per basic and diluted
share, in the same period of 2013.
As of June 30, 2014, cash and cash equivalents totaled $89.6
million, compared to $107.2 million as of December 31, 2013. Net cash used in operating activities was $11.4 million during the
first half of 2014. Net cash used in investing activities was $5.7 million, which was primarily used for payment of property, plant
and equipment for the Company's Changping facility. Net cash provided by financing activities was $0.9 million during the first
half of 2014, including loan proceeds of $8.9 million and loan repayment of $8.5 million. As of June 30, 2014, the Company
had $36.0 million of bank loans due within one year. Sinovac's cash and cash equivalents position of $89.6 million is sufficient
to meet both these loan repayment obligations as well as the Company's operational requirements.
Sinovac will host a conference call on Friday, August 15, 2014
at 8:00 a.m. ET (August 15, 2014 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update
on recent corporate developments. To access the conference call, please dial 1-877-407-9039 (USA) or 1-201-689-8470 (International).
A replay of the call will be available from 11:00 a.m. ET on August 15, 2014 through August 29, 2014. To access the replay, please
dial 1-877-870-5176 (USA) or 1-858-384-5517 (International) and reference the replay pin number 13587706.
A live audio webcast of the call will also be available on the
Investor Relations section of the Company's website at www.sinovac.com. A webcast replay will be available on the Company's website
for 30 days following the call, beginning August 15, 2014.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company
that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious
diseases. Sinovac's product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza
(avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009, Sinovac was the first company worldwide to receive
approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling
program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. Sinovac
has filed a new drug application with the China Food & Drug Administration for its proprietary enterovirus 71 vaccine, having
been proven effective in preventing hand, foot and mouth disease in infants and children during its Phase III clinical trial.
The Company is currently developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal
polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China,
while also exploring growth opportunities in international markets. The Company has exported select vaccines to Mexico, Mongolia,
Nepal, and the Philippines, and was recently granted a license to commercialize its hepatitis A vaccine in Chile. For more information,
please visit the Company's website at www.Sinovac.com .
The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.
To receive a free e-mail notification whenever Sinovac Biotech
makes a similar move, sign up!